A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. - Test2 - elhamkhani - TriplyDB

A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.

A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.

http://www.wikidata.org/entity/Q34376968

about

Cytokine-Induced Modulation of Colorectal Cancer Interleukin 12: still a promising candidate for tumor immunotherapy?HemaMax™, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates Way to go to exploit NK cells' versatile talents for cancer immunotherapy.A quantitative systems approach to identify paracrine mechanisms that locally suppress immune response to Interleukin-12 in the B16 melanoma model.New insights into IL-12-mediated tumor suppression.NK cell-based immunotherapy for treating cancer: will it be promising?New developments in the treatment of metastatic gastric cancer: focus on trastuzumab Abrogation of TNFα production during cancer immunotherapy is crucial for suppressing side effects due to the systemic expression of IL-12.Differential growth inhibition of cerebral metastases by anti-angiogenic compounds A multiscale systems perspective on cancer, immunotherapy, and Interleukin-12 Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12.Natural killer cells: role in local tumor growth and metastasis Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy.Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.Antiangiogenic therapies in early-stage breast cancer.Biological role of NK cells and immunotherapeutic approaches in breast cancer.IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production.Sorafenib: where do we go from here?Promising systemic immunotherapies in head and neck squamous cell carcinoma.The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity.Combining immunotherapy and targeted therapies in cancer treatment.Combination strategies to enhance antitumor ADCC.Advances in biomarkers for esophageal cancer.Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.Emerging immunotherapy strategies in breast cancer.Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12.An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells.Expression of interleukin-12 by adipose-derived mesenchymal stem cells for treatment of lung adenocarcinoma Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.Harnessing the immune system in the battle against breast cancer.Co-stimulation of the fc receptor and interleukin-12 receptor on human natural killer cells leads to increased expression of cd25.Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.

P2860

Q26752374-8F79C7C9-DDF9-4E2A-9F1B-04A87D9D1E9E Q26861559-741BB1A2-60C4-46F6-A874-EBFEAD70EA9F Q28731776-F893202F-241B-4C62-9934-BD6D7E2812C9 Q34302440-1E79F1EF-453F-4CE0-822A-71DAD0E88AC2 Q34331673-4DD7F535-9D6F-4EC9-8BC2-E6D46F688AFD Q34436897-84717751-EF2B-495B-8C02-730009804DF1 Q34729280-06496412-C6AA-416D-AA7E-2A5C7439AA1D Q34883258-39767E8C-7E45-4C95-8093-D4FF0F921EC8 Q35108695-B9E4E20C-9221-4429-BC83-AF2083AE6C33 Q35304863-83D0E421-75BC-4012-9503-E76E9AD87F74 Q35624686-7628837F-2883-4206-936A-6FCFA57C069E Q35779345-3EB609C7-6EE6-4CA4-B5DD-575C9750FC69 Q35780315-0D87E202-C456-4862-A9E5-2FE183DE1D92 Q35809223-D0B128C9-F8FC-4D4C-ADC7-D0768F26540F Q35905953-3D76CD4D-CF36-46AA-BC18-2BA5AEFDD5F2 Q35962555-CA40DCE4-6ECA-486B-ABB8-276E60B1F175 Q36109555-961DDED3-C4BF-4A01-B1D2-3AFAA41C5DF0 Q36204962-0C11E91D-F584-4E53-9966-4B084E5FD3DF Q36318210-C2E49723-DAC4-47C5-80B2-ECEFCC537132 Q36460884-BB4C8AEF-369B-486C-95D7-19C68ADECD07 Q36671364-580D0F12-399A-4A5D-A743-567F3F22CCE2 Q36708741-86C872EB-D14E-424F-A817-C4C604211883 Q36883848-4E4C7C01-A6B3-457B-BF31-CCBFCBAAD1B8 Q37413162-0B00A6C2-7E69-406A-85A0-D00435531F3D Q37995939-28B4D110-75B0-491E-AB55-79EE3F3D0840 Q38014085-D1351F28-AF71-4BD4-ACD2-5341F981BA9D Q38153443-E761835A-09B3-49F6-8D48-35B06F724347 Q38162129-95C1BC67-8E06-483D-BBA8-36F0B158F301 Q38184650-D9EA929B-2EDA-4EF1-B74E-60D560A7B4B9 Q38412375-1A6A2AA3-307A-424D-9133-2FA0D02658A4 Q38703318-3E1F3E05-45E6-447E-BAF0-823A4B8C329F Q39231967-3A075295-B844-4973-BDAD-E49BCB427FFA Q40642974-C2A71D62-8BDA-457C-9D97-2FF9731F0AF0 Q41340974-7998F133-196C-4BF4-9C1A-8012851FD9CC Q47156322-16B72A45-7131-44FA-8680-D4BEE1393AED Q49884762-36EB7959-E224-424C-BE21-D0A4A0882047 Q50545440-B38F64E4-5079-4E93-8C29-5EA395C487CF Q54594739-A09D0EA8-51A4-495C-A788-24BB68F346B0

P2860

A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.

http://www.wikidata.org/entity/Q34376968

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.

@ast

A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.

@en

A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.

@nl

type

label

A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.

@ast

A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.

@en

A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.

@nl

prefLabel

A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.

@ast

A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.

@en

A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.

@nl

P1433

Q34376968-8E9207C6-C8FA-4AE3-AC26-96D262341612

P1476

Q34376968-8A2684A7-2732-4A1A-8E53-57C2ED811552

P2093

Q34376968-15F34E60-B29F-460D-8165-54E79C96CA71

Q34376968-1C0ED170-36AB-45AE-A497-9A5E95D2CA0E

Q34376968-1EBB9CB8-ED91-47DE-89C4-9FC0961C4108

Q34376968-38729C84-BF9D-4852-9A86-CD94493BC923

Q34376968-8A435B43-A429-4090-B959-61825C7E61C1

Q34376968-9002E6D2-A83D-4825-B5CC-CF0B2C790162

Q34376968-9D986379-A7D7-45E7-AC99-63E04B1B965B

Q34376968-C45659D5-F2AF-4293-8D7B-61C98765D709

Q34376968-FF8B0C42-2E09-47FA-ABB7-94895FFA3E89

P2860

Q34376968-08AE55E1-5D8B-483C-B6ED-0466EEAF9E0E

Q34376968-08B61F58-FAB3-4377-A79A-3D4BA8CCE50A

Q34376968-0AD2F777-473C-4607-8C7A-29BE685CAF84

Q34376968-28AF4230-32EB-4CB8-AB1F-3D94557AC1B0

Q34376968-29266A54-C332-4AA9-A556-758C167C9FBD

Q34376968-33D3340B-1887-468C-B070-C7673D6C193D

Q34376968-4EE65C8E-5902-49D4-A090-D771601DB9A0

Q34376968-655E1818-B221-4118-B007-6DE5CD93E61C

Q34376968-6ACAB01F-9D02-4FF3-B8C1-A6FE255E6AB0

Q34376968-6BEE1EA2-AB29-44A2-8DCF-B985F0BEB9DC

P304

Q34376968-0C6A3670-A4A2-4ECC-A37B-A700B442F241

P31

Q34376968-3C7D1178-B30E-4168-9BC8-A98575349D36

P356

Q34376968-A353A327-24D9-4B9E-99E6-1DA3F1FB1D4D

P433

Q34376968-11129866-6A20-4A64-8785-973856556DD0

P478

Q34376968-C1DF9437-7750-40B0-BC34-5DF8D99F9A84

P50

Q34376968-836BA7BF-BD88-41D1-9FC3-114B86F277ED

P577

Q34376968-183E40B1-AA18-4293-AF41-4BAAC4B8EFAF

P698

Q34376968-D6D816A1-50A0-42DA-B58B-23F5032637FF

P921

Q34376968-5BC577E2-33D7-47EB-A334-898B1ADDF32A

Q34376968-E1BE0C79-64CD-430E-A53C-F54E36F742C6

Q34376968-a1409b74-ab48-44ae-b20d-7e95b0be1650

P932

Q34376968-C5FEE4EB-7C4C-47B2-B20D-4588FCFB8766

P356

1535-7163.MCT-09-0820

P1433

Molecular Cancer Therapeutics

P1476

A phase I trial of paclitaxel ...... 2/neu-expressing malignancies.

@en

P2093

Amy K Ferketich

http://www.w3.org/2001/XMLSchema#string

Bhuvanaswari Ramaswamy

http://www.w3.org/2001/XMLSchema#string

Charles L Shapiro

http://www.w3.org/2001/XMLSchema#string

Donn C Young

http://www.w3.org/2001/XMLSchema#string

Kristan D Guenterberg

http://www.w3.org/2001/XMLSchema#string

Michael R Grever

http://www.w3.org/2001/XMLSchema#string

Tammy A Lamb

http://www.w3.org/2001/XMLSchema#string

Tanios S Bekaii-Saab

http://www.w3.org/2001/XMLSchema#string

William E Carson

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

The biology of human natural killer-cell subsets.

Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma.

Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.

Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

P304

2983-2991

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-09-0820

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19887543

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

2996611

http://www.w3.org/2001/XMLSchema#string